Volume 36, Issue 3 , Pages 425-430, March 2010
Repeatability of corneal power and wavefront aberration measurements with a dual-Scheimpflug Placido corneal topographer
Purpose
To evaluate the repeatability of the Galilei dual-Scheimpflug analyzer in measuring corneal curvature, wavefront aberrations, pachymetry, and anterior chamber depth (ACD).
Setting
Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA.
Methods
Three consecutive measurements were performed in 1 eye of each subject. The following were evaluated: (1) mean total corneal power at the central, paracentral, and peripheral zones (0.0 to 4.0 mm, 4.0 to 7.0 mm, and 7.0 to 8.0 mm, respectively) and posterior corneal power (Kavg); (2) corneal higher-order wavefront aberrations (6.0 mm pupil); (3) mean pachymetry at the central, paracentral, and peripheral zones; and (4) ACD. Repeatability was assessed by calculating the within-subject standard deviation (SD), coefficient of variation (COV), and intraclass correlation coefficient (ICC).
Results
The study enrolled 20 subjects. The SD was 0.09 diopter (D), 0.05 D, and 0.19 D for central, paracentral, and peripheral total corneal power, respectively, and 0.03 D for posterior Kavg. The COV ranged from 0.10% to 0.35%, and the ICC was 0.996 or more (P<.001). For 3rd-order coma and trefoil, the SD was 0.08 μm and 0.09 μm, respectively. For 4th-order spherical aberration, astigmatism, and tetrafoil, the SDs were lower (0.02 μm, 0.04 μm, and 0.09 μm, respectively). The SD was 1.68 μm, 1.98 μm, and 2.82 μm for central, paracentral, and peripheral pachymetry, respectively, and 0.04 mm for ACD.
Conclusion
Dual-Scheimpflug measurements of corneal power, pachymetry, ACD, and corneal aberrations for Zernike terms in the middle of the Zernike tree showed excellent repeatability.
Financial Disclosure
No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes.
To access this article, please choose from the options below
Additional financial disclosures: Dr. Wang received research support and Dr. Shirayama received travel support from the Ziemer Group, Port, Switzerland.
Supported in part by an unrestricted grant from Research to Prevent Blindness, New York, New York, USA.
PII: S0886-3350(09)01129-8
doi:10.1016/j.jcrs.2009.09.034
© 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Volume 36, Issue 3 , Pages 425-430, March 2010
